List of bibliographic references
Number of relevant bibliographic references: 10.
List of associated KwdEn.i
Nombre de
documents | Descripteur |
|---|
| 7 | Human |
| 6 | Aged |
| 6 | Humans |
| 6 | Parkinson disease |
| 5 | Female |
| 4 | Male |
| 4 | Middle Aged |
| 3 | Dose-Response Relationship, Drug |
| 3 | Parkinson's disease |
| 3 | Treatment |
| 2 | Antiparkinson Agents (adverse effects) |
| 2 | Antiparkinson Agents (therapeutic use) |
| 2 | Antiparkinson agent |
| 2 | Case study |
| 2 | Chemotherapy |
| 2 | Comparative study |
| 2 | Degeneration |
| 2 | Dyskinesia |
| 2 | Energy Metabolism (physiology) |
| 2 | Levodopa (adverse effects) |
| 2 | Levodopa (therapeutic use) |
| 2 | Neurologic Examination (drug effects) |
| 2 | Nigrostriatal pathway |
| 2 | Parkinson Disease (complications) |
| 2 | Parkinson Disease (drug therapy) |
| 2 | Symptomatology |
| 1 | Administration, Oral |
| 1 | Adrenergic alpha-Antagonists (adverse effects) |
| 1 | Adrenergic alpha-Antagonists (therapeutic use) |
| 1 | Adult |
| 1 | Animals |
| 1 | Antagonist |
| 1 | Anti-Anxiety Agents (therapeutic use) |
| 1 | Apomorphine (therapeutic use) |
| 1 | Apraxia |
| 1 | Apraxias (radionuclide imaging) |
| 1 | Aspartic Acid (analogs & derivatives) |
| 1 | Aspartic Acid (analysis) |
| 1 | Aspartic Acid (metabolism) |
| 1 | Basal Ganglia Diseases (complications) |
| 1 | Blood Glucose (metabolism) |
| 1 | Brain Chemistry (physiology) |
| 1 | Brain Diseases (complications) |
| 1 | Brain Diseases (physiopathology) |
| 1 | Brain Mapping |
| 1 | Cerebral Cortex (radionuclide imaging) |
| 1 | Classification |
| 1 | Clonazepam (therapeutic use) |
| 1 | Corpus Striatum (physiopathology) |
| 1 | Corpus Striatum (radionuclide imaging) |
| 1 | Corpus striatum |
| 1 | Corticobasal degeneration |
| 1 | Data Interpretation, Statistical |
| 1 | Deoxyglucose (analogs & derivatives) |
| 1 | Deoxyglucose (metabolism) |
| 1 | Diagnosis, Differential |
| 1 | Dominance, Cerebral (physiology) |
| 1 | Dyskinesia, Drug-Induced (diagnosis) |
| 1 | Dyskinesia, Drug-Induced (drug therapy) |
| 1 | Dyskinesia, Drug-Induced (etiology) |
| 1 | Dystonia |
| 1 | Dystonia (metabolism) |
| 1 | Electromyography |
| 1 | Exploration |
| 1 | Fluorodeoxyglucose |
| 1 | Fluorodeoxyglucose F18 |
| 1 | Follow-Up Studies |
| 1 | Glutamic Acid (metabolism) |
| 1 | Glutamine (metabolism) |
| 1 | Haplorhini |
| 1 | Idazoxan |
| 1 | Idazoxan (adverse effects) |
| 1 | Idazoxan (therapeutic use) |
| 1 | Image Processing, Computer-Assisted |
| 1 | Injections, Subcutaneous |
| 1 | Instrumental stimulation |
| 1 | Leg |
| 1 | Levodopa |
| 1 | L‐DOPA, dyskinesia |
| 1 | Magnetic Resonance Spectroscopy |
| 1 | Meige Syndrome (drug therapy) |
| 1 | Motor Cortex (metabolism) |
| 1 | Movement Disorders (radionuclide imaging) |
| 1 | Multiple system atrophy |
| 1 | Muscle Rigidity (radionuclide imaging) |
| 1 | Neostriatum (metabolism) |
| 1 | Nerve Degeneration |
| 1 | Nerve Degeneration (physiology) |
| 1 | Neural Pathways (metabolism) |
| 1 | Orthostatism |
| 1 | Pallidum |
| 1 | Parkinson Disease (physiopathology) |
| 1 | Pathophysiology |
| 1 | Phase II trial |
| 1 | Phenomenology |
| 1 | Pilot Projects |
| 1 | Positron emission tomography |
| 1 | Severity of Illness Index |
| 1 | Somatosensory Cortex (metabolism) |
| 1 | Striatonigral degeneration |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/France/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i -k "M. Vidailhet"
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i \
-Sk "M. Vidailhet" \
| HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= France
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= M. Vidailhet
}}
| This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024 |  |
